Bristol Myers Squibb (BMY) Stock
Diversified biopharmaceutical company with oncology and immunology medicines. Here's the price, business snapshot, and what's worth knowing about Bristol Myers Squibb in August 2026.
Bristol-Myers Squibb (BMY) is a large, diversified biopharmaceutical company with a market cap of about $90.7bn. Investors should know it combines an established portfolio of marketed medicines—particularly in oncology, haematology and immunology—with a deep pipeline and substantial R&D spending. Key revenue drivers include immuno‑oncology and speciality medicines, though some legacy products face generic competition as patents expire. The 2019 Celgene acquisition broadened product mix but increased leverage, making cash generation and debt management important considerations. Regulatory outcomes, trial results and competitive approvals can move the share price materially. BMY typically pays a dividend, which may appeal to income‑minded investors, but dividends and share values can fall. This summary is for educational purposes only and not personalised advice; always consider your risk tolerance and do further research or speak to a financial adviser before investing.
Why It’s Moving
BMY slips into analyst crosshairs as a fast rally collides with fading visibility
- Analysts are turning more cautious after BMY’s recent rally, arguing the move has already priced in a lot of the good news and leaves less room for further upside.
- Barclays downgraded the stock to Underweight, saying long-term visibility remains murky as Bristol Myers still has to replace older drugs that are facing erosion.
- The latest caution is also tied to recurring headwinds in the pharma sector, including patent expirations, delayed pipeline readouts, and pressure around drug-pricing policy.
BMY slips into analyst crosshairs as a fast rally collides with fading visibility
- Analysts are turning more cautious after BMY’s recent rally, arguing the move has already priced in a lot of the good news and leaves less room for further upside.
- Barclays downgraded the stock to Underweight, saying long-term visibility remains murky as Bristol Myers still has to replace older drugs that are facing erosion.
- The latest caution is also tied to recurring headwinds in the pharma sector, including patent expirations, delayed pipeline readouts, and pressure around drug-pricing policy.
When is the next earnings date for Bristol Myers Squibb (BMY)?
The next earnings date for BMY is expected to be October 29, 2026. This release should cover third-quarter 2026 results. Bristol Myers Squibb has typically reported earnings in late October based on its recent reporting pattern.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Bristol Myers Squibb's stock, believing it may rise in value soon.
Financial Health
Bristol Myers Squibb is performing well with strong profits and cash flow, indicating solid financial health.
Dividend
Bristol Myers Squibb's dividend yield of 2.94% offers moderate returns for dividend-seeking investors. If you invested $1000 you would be paid $29.40 a year in dividends (based on the last 12 months).
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Discover More Opportunities
AbbVie
Abbvie is a research-based biopharmaceutical company that develops and markets advanced therapies to address complex medical conditions.
ASTRAZENECA PLC
AstraZeneca is a global biopharmaceutical company focused on discovering, developing, manufacturing, and commercializing innovative medicines.
AMGEN INC
Amgen is a global biotechnology company that focuses on discovering, developing and commercializing treatments for unmet medical needs.
Baskets Featuring BMY
AI-Driven Pharma Stocks | Pipeline Innovation
Novo Nordisk's partnership with OpenAI highlights a massive shift as major drugmakers integrate generative AI into their core operations. This basket captures the pharmaceutical giants optimizing their pipelines alongside the tech titans providing the underlying AI infrastructure.
Published: 15 April 2026
Explore BasketUS Pharma Reshoring | CDMOs & Supply Chain Stocks
The Trump administration is implementing sweeping 100% tariffs on imported brand-name drugs to force pharmaceutical companies into producing their medicines stateside. This aggressive policy shift creates a highly lucrative environment for US-based contract manufacturers and domestic healthcare supply chain operators as global drugmakers rush to reshore their operations.
Published: 4 April 2026
Explore BasketPharma Manufacturing | What's Next After TrumpRx
GlaxoSmithKline and Amgen are the latest pharmaceutical giants to join the TrumpRx platform, offering direct-to-consumer medications at reduced prices while committing to massive U.S. manufacturing investments. This evolving landscape creates compelling investment opportunities in domestic drug production facilities, supply chain logistics, and digital health aggregators that help patients navigate new pricing structures.
Published: 14 March 2026
Explore BasketFed Division: Fortress Balance Sheets Explained
The Federal Reserve is showing a rare public division on whether to raise, lower, or hold interest rates, creating uncertainty for the markets. This theme focuses on investing in companies with strong financial health that are better equipped to handle the market volatility resulting from unpredictable monetary policy.
Published: 19 February 2026
Explore BasketBlood Thinner Breakthrough Explained | Market Overview
Bayer's successful Phase III trial for its new blood thinner has demonstrated a significant reduction in stroke recurrence. This breakthrough positions the company favorably against competitors and highlights an investment opportunity in the evolving landscape of cardiovascular treatments.
Published: 6 February 2026
Explore BasketPharma Buyouts Explained | Healthcare M&A Analysis
Merck's decision to end its acquisition talks with Revolution Medicines highlights the high-stakes environment for biotech M&A. This failed deal could signal an opportunity for other pharmaceutical giants to acquire promising oncology assets, creating a ripple effect across the sector.
Published: 26 January 2026
Explore BasketU.S. Drug Manufacturing | Multi-Billion Investment Push
Johnson & Johnson is the latest major drugmaker to lower U.S. prices in exchange for tariff exemptions, joining a broad industry trend. This government-led initiative is sparking a multi-billion dollar investment wave into domestic manufacturing, creating a significant opportunity for companies supporting the U.S. pharmaceutical supply chain.
Published: 10 January 2026
Explore BasketDrug Pricing Deals Drive US Manufacturing in 2025
Johnson & Johnson secured a deal with the U.S. government to lower drug prices in exchange for tariff exemptions, expanding on a major policy trend. This theme identifies opportunities among pharmaceutical companies and domestic manufacturers benefiting from government incentives to onshore production.
Published: 9 January 2026
Explore BasketRadiopharma Revolution: Promise Meets Market Risk
Aktis Oncology's highly successful and upsized IPO, strongly backed by pharma giant Eli Lilly, signals a surge of investor confidence in radiopharmaceutical cancer therapies. This theme focuses on the companies poised to ride this wave of investment and innovation in one of biotech's most promising frontiers.
Published: 9 January 2026
Explore BasketWhy You’ll Want to Watch This Stock
Oncology-led revenue engine
BMY’s oncology and haematology drugs drive sales and headline growth, though trial outcomes and competition can cause swings in performance.
Pipeline and R&D programme
A substantial pipeline offers upside if trials succeed, but R&D failures and regulatory delays are common and can affect value.
Cash flow and balance
Established medicines and partnerships support cash flow, yet patent cliffs and post-acquisition debt make balance-sheet management important.
Compare Bristol Myers Squibb with other stocks
AbbVie vs Bristol Myers Squibb
AbbVie vs Bristol Myers Squibb: Stock Comparison
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
